Gameto is a private, clinical-stage biotech founded in 2020, leveraging a proprietary induced pluripotent stem cell (iPSC) platform to engineer ovarian support cells. Its lead asset, Fertilo, is in Phase 3 trials for improving IVF outcomes, while earlier-stage programs target ovarian disease (Deovo) and menopause (Ameno). The company is backed by venture capital and a recent award from ARPA-H, positioning it at the forefront of innovation in the underserved women's health market.
Proprietary iPSC (induced pluripotent stem cell) platform to engineer ovarian support cells ('ovary-in-a-dish' technology) for ex vivo egg maturation and cell therapy applications.
Funding History
3
Total raised:$55M
Series B$33MTwo Sigma Ventures
Series A$20MFuture Ventures
Seed$2MUndisclosed
Opportunities
The global infertility and underserved menopause markets represent multi-billion dollar opportunities with high unmet need.
Gameto's platform technology allows it to address multiple indications with a single core innovation, creating significant potential for pipeline expansion and value creation.
Government backing via ARPA-H provides non-dilutive funding and validation.
Risk Factors
The company faces significant clinical risk as its lead asset undergoes Phase 3 testing.
The novel iPSC-derived cell therapy approach carries inherent technology and manufacturing scalability risks.
Market adoption for a new IVF protocol and a first-in-class menopause cell therapy is uncertain and faces potential reimbursement challenges.
Competitive Landscape
Gameto is a first-mover in applying engineered iPSC-derived ovarian cells to fertility and menopause. It faces competition from established IVF medication and device companies, as well as other biotechs exploring in vitro gametogenesis (IVG) or alternative menopause therapies. Its proprietary platform and clinical progress provide a competitive moat.
